Combination therapeutic approaches for the management of invasive aspergillosis in organ transplant recipients

Mycoses

Volumn 51, Issue 2, 2008, Pages 99-108

  Singh, Nina ^a   Pursell, Kenneth J ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Antifungal therapy; Aspergillosis; Aspergillus; Combination antifungal therapy; Transplants

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CYCLOSPORIN A; FLUCONAZOLE; GAMMA INTERFERON; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MYCOPHENOLIC ACID; POSACONAZOLE; RAVUCONAZOLE; RIBAVIRIN; TACROLIMUS; VORICONAZOLE;

ADJUVANT THERAPY; ASPERGILLOSIS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; COMBINATION CHEMOTHERAPY; CRYPTOCOCCOSIS; DRUG EFFICACY; DRUG POTENTIATION; GRAFT FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; LUNG ASPERGILLOSIS; MONOTHERAPY; MORTALITY; NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CYTOKINES; DRUG THERAPY, COMBINATION; GUINEA PIGS; HUMANS; IMMUNOTHERAPY; ORGAN TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

ASPERGILLUS;

EID: 38849095904     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2007.01479.x     Document Type: Review

References (106)

1. Gavalda J, Len O, San Juan R et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005 41:52 9.
2. Minari A, Husni R, Avery RK. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transplant Infect Dis 2002 4:195 200.
3. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993 16:677 88.
4. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005 18:44 69.
5. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999 78:123 38.
6. Kusne S, Dummer JS, Singh N et al. Infections after liver transplantation, an analysis of 101 consecutive cases. Medicine 1988 67:132 43.
7. Singh N, Paterson DL, Gayowski T et al. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001 71:910 3.
8. Singh N, Arnow PM, Bonham A et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997 64:716 20.
9. Linden PK, Coley K, Fontes P et al. Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B. Clin Infect Dis 2003 37:17 25.
10. Steinbach WJ. Combination antifungal therapy for invasive aspergillosis-It is indicated? Medical Mycology 2006 44:373 82.
11. Johnson MD, MacDougall C, Ostrosky-Zeichner L et al. Combination antifungal therapy. Antimicrob Agents Chemotherap 2004 48:693 715.
12. Kitahara M, Seth VK, Medoff G et al. Activity of amphotericin B, 5-flurocytosine, and rifampin against six clinical isolates of Aspergillus. Antimicrob Agents and Chemotherap 1976 9:915 9.
13. Denning D, Hanson LH, Perlman AM et al. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diag Microbiol Infect 1992 15:21 34.
14. Hughes CE, Harris C, Moody JA et al. In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp. Anticirob Agents Chemotherap 1984 25:560 2.
15. Schmitt HJ, Bernard EM, Edwards FF et al. Combination therapy in rat model of pulmonary aspergillosis. Mycoses 1991 34:281 5.
16. Patterson TF, Kirkpatrick WR, White M et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. 13 Aspergillus Study Group. Medicine 2000 79:281 2.
17. Petraitis V, Petraitiene R, Sarafandi A et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003 187:1834 43.
18. Kirkpatrick WR, Perea S, Coco BJ et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemotherap 2002 46:2564 8.
19. Arikan S, Lozano-Chiu M, Paetznick V et al. In vitro synergy of caspofungin and amphtericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemotherap 2002 46:245 7.
20. Philip A, Odabasi Z, Rodriguez J et al. In vitro synergy testing of Anidulafungin with Itraconazole, Voriconazole, and Amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemotherap 2005 49:3572 4.
21. phox-/- mouse model of chronic granulomatous disease. Antimicrob Agents Chemotherap 2006 50:422 7.
22. Polak A. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy 1987 33:381 95.
23. Kontoyiannis DPR, Lewis RE, Sagar N et al. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy. Antimicrob Ag Chemother 2000 44:2915 8.
24. Meletiadis J, Petraitis V, Petraitiene R et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 2006 194:1008 18.
25. Chandrasekar PH, Cutright JL, Manavathu EK. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clinical Microbiol Infect 2004 10:925 8.
26. Najvar L, Cacciapuoti A, Hernandez SHJ et al. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories. Antimicrob Agents Chemother 2004 3:758 64.
27. Clemons KV, Parmar R, Martinez M et al. Efficacy of abelcet alone, or in combination therapy against experimental central nervous system aspergillosis. Antimicrob Chemotherap 2006 58:466 9.
28. O'Shaughnessy E, Meletiadis J, Stergiopoulou T et al. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergilus species. J Antimicrobiol Chemotherap 2006 58:1168 76.
29. Marr KA, Boeckh M, Carter RA et al. Combination antifungal therapy for invasive apergillosis. Clin Infect Dis 2004 39:797 802.
30. Kontoyiannis DP, Lewis RE, Lionakis MS et al. Sequential exposure of Aspergillus fumigatus to itraconazole and caspofungin: evidence of enhanced in vitro activity. Diag Microbiol Infect Dis 2003 47:415 9.
31. Kontoyiannis DP, Lewis RE, Osherov N et al. Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 2003 51:313 6.
32. Maertens J, Glasmacher A, Herbrecht R et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive Aspergillus. Cancer 2006 107:2888 97.
33. Caillot D, Thiebaut A, Herbrecht R et al. Liposomal Amphotericin B Standard Dose in Combination With Caspofungin Versus Liposomal Amphotericin B High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromised Patients: Randomized Pilot Study (Combistrat Trial). Paris, France:International Society of Human and Animal Mycology, 2006.
34. Damaj G, Ivanov V, Le Brigand B et al. Rapid improvement of disseminated aspergillosis with caspofungin/voriconaole combination in an adult leukemic patient. Ann Hematol 2004 83:390 3.
35. Tascini C, Tagliaferri E, Iapoce R et al. Caspofungin in combination with itraconazole and amphotericin B for the treatment of invasive aspergillosis in humans with a method to test ex vivo synergism. Clin Microbiol Infect 2003 9:901 2.
36. Singh N, Limaye A, Forrest G et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter observational trial. Transplantation 2006 81:320 6.
37. Sole A, Morant P, Salavert M et al. Aspergillus in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005 11:359 65.
38. Odom A, Muir S, Lim E et al. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J 1997 16:2576 89.
39. Cruz MC, Goldstein AL, Blankenship JR et al. Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J 2002 21:546 59.
40. Steinbach W, Cramer RA, Perfect BZ et al. Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryotic Cell 2006 5:1091 103.
41. Steinbach WJ, Singh N, Miller JL et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and non-transplant patients. Antimicrob Ag Chemother 2004 48:4922 5.
42. Sehgal SN, Baker H, Venzina C. Rapamycin (AY-22,989), a new antifungal antibiotic: II. Fermentation, isolation and characterization. J Antibiot 1975 28:727.
43. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22989), a new antifungal antibiotic.Taxonomy of the producing Streptomycete and isolation of the active principle. J Antibiot 1975 28:721 6.
44. Cruz MC, Goldstein AL, Blankenship J et al. Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. Antimicrob Agents Chemotherap 2001 45:3162 70.
45. High KP. The antimicrobial activities of cyclosporine, FK506, and rapamycin. Transplantation 1994 57:1689 700.
46. Marchetti O, Moreillon P, Glauser MP et al. Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemotherap 2000 44:2373 81.
47. 1, fluconazole and the pneumocandin MD-0991 caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother 2000 44:739 46.
48. Patterson TF, Kirkpatrick WR, White M et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine 2000 79:250 60.
49. Ramgolam V, Ang SG, Lai YH et al. Traditional Chinese medicines as immunosuppressive agents. Ann Acad Med Singapore 2000 29:11 6.
50. Liles WC, Huang JE, VanBurik J et al. Granulocyte colonystimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis 1997 175:1012 5.
51. Vora S, Chauhan S, Brummer E et al. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor. Antimicrob Agents Chemotherap 1998 42:2299 303.
52. Gil-Lamaignere C, Winn R, Simitsopoulou M et al. Interferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against scedosporium spp. Med Mycol 2005 43:253 60.
53. Gonzales C, Lyman CA, Lee S et al. Recombinant human macrophage colony-stimulating factor augments pulmonary host defenses against Aspergillus fumigatus. Cytokine 2001 15:87 95.
54. Johnson C, Edmiston C, Zhu Y et al. A murine model of invasive aspergillosis:variable benefit of interferon-gamma administration under in vetro and in vivo conditions. Surg Infect 2005 6:397 407.
55. Roilides E, Lyman CA, Mertins S et al. Ex vivo effects of macrophage colony-stimulating factor on human monocyte activity against fungal and bacterial pathogens. Cytokinie 1996 8:42 8.
56. Todeschini G, Murari C, Bonesi R et al. Invasive aspergillosis in neutropenic patients: rapid neutrophil recovery is a risk factor for severe pulmonary complications. Eur J Clin Invest 1999 29:453 7.
57. Wang J, Chen Z, Colella S et al. Chemotactic activity of human recombiant granulocyte-colony stimulating factor. Blood 1988 72:1456 60.
58. Weisbert R, Golde D. Physiology of granulocyte and macrophage colony-stimulating factors in host defense. Hem Onc Clin NA 1989 3:401 9.
59. Sullivan G, Carper J, Mandell GL. The effect of three recombinant haematopoietic growth factors (GM-CAF, G-CSF, and IL-3) on phagocytic oxidative activity. Blood 1993 81:1863 70.
60. Roilides E, Uhlig K, Venson D et al. Enhancement o oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immunol 1993 61:1185 93.
61. Natarajan U, Brummer E, Stevens DA. Effect of colony-stimulating factor on the condidacidal activity of polymorphonuclear neutrophils and their collaboration with fluconazole. Antimicrob Agents Chemotherap 1997 41:1575 8.
62. Gaviria J, van Burik J, Dale DC et al. Comparison of interferon-y, granulocye colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. J Infect Dis 1999 179:1038 41.
63. Salant D, Glover A, Anderson R et al. Depressed neutrophil chemotaxis in patients with chronic renal failure and after renal transplantation. J Lab Clin Med 1976 88:536 45.
64. Hutchinson P, Chadban S, Atkins R et al. Laboratory assessment of immune function in renal transplant patients. Nephrol Dial Transplant 2003 18:983 9.
65. Pursell K, Verral S, Daraiesh F et al. Impaired phagocytic respiratory burst responses to opportunistic fungal pathogens in transplant recipients: in vitro effect of r-metHuG-CSF (Filgrastim). Transplant Infect Dis 2003 5:29 37.
66. Sionov E, Mendlovic S, Segal E. Experimental systemic aspergillosis: treatment with polyene and caspofungin combination and G-CSF. J Antimicrob Chemotherap 2005 56:594 7.
67. Patera A, Menzel F, Jackson C et al. Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis. Antimicrob Agents Chemotherap 2004 48:3154 8.
68. Hazel D, Newland A, Kelsey S. Granulocyte-colony stimulating factor increases the efficacy of conventional amphotericin in the treatment of presumed deep-seated fungal infection in neutropenic patients following intensive chemotherapy or bone marrow transplantation for haematological malignancies. Hematology 1999 4:305 11.
69. Foster P, Mital D, Sankary H et al. The use of granulocyte colony-stimulating factor after liver transplantation. Transplantation 1995 59:1557 63.
70. Winston D, Foster P, Somberg K et al. Randomized, placebo-controlled, double-blind, multicenter trial of efficacy and safety of granulocyte colony-stimulating factor in liver transplant recipients. Transplantation 1999 68:1298 304.
71. Tajima A, Aso Y, Kawabe K et al. Colony-stimulating factor for treatment of leukopenia after kidney allografting. Transplant Proceed 1991 23:1369 70.
72. Peddi VR, Hariharan S, Schroeder T et al. Role of granulocyte colony-stimulating factor (G-CSF) in reversing neutropenia in renal allograft recipients. Transplantation 1996 10:20 3.
73. Moghal N, Milford D, Darbyshire P. Treatment of neutropenia in a renal transplant recipient with ganulocyte colony-stimulating factor. Ped Nephrol 1998 12:14 5.
74. Schmaldienst S, Bekeski G, Deicher R et al. Recombinant human granulocyte colony-stimulating factor after kidney transplantation: a retrospective analysis to evaluate the benefit or risk of immunostimulation. Tansplantation 2000 69:527 31.
75. Turgeon N, Hovingh G, Fishman J et al. Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients. Transplant Infect Dis 2000 2:15 21.
76. Neumann U, Puhl G, Bahra M et al. Treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon alfa-2B plus ribavirin. Transplantation 2006 82:43 7.
77. Armitage J. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1998 12:4491 508.
78. Hubel K, Dale D, Liles W. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J Infect Dis 2002 185:1490 501.
79. Antachopoulos C, Roilides E. Cytokines and fungal infections. Br J Haematol 2005 129:583 96.
80. Berghmans T, Paesmans M, Lafitte J et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients: as systematic review of the literature with meta-analysis. Cancer 2002 10:181 8.
81. Bodey G, Anaissie E, Gutterman J et al. Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. Eur J Microbiol Infect Dis 1994 13:18 22.
82. Boots R, Paterson D, Allworth A et al. Successful treatment of post-influenza pseumembranous necrotizing bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF. Thorax 1999 54:1047 9.
83. Abu JL, Haidar R, Bitar F et al. Aspergillus vertebral osteomyelitis in a child with a primary monocyte kiling defect: response to GM-CSF therapy. J Infect 2000 41:97 100.
84. Trachana M, Roilides E, Gompakis N et al. Case report: hepatic abscesses due to Aspergillus terreus in an immunodeficient child. Mycoses 2001 44:415 8.
85. Squiers E, Elkhammas E, Henry M. Use of granulocyte-macrophage colony-stimulating factor for reversal of neutreopenia following combined kidney-pancreas transplantation. Transplant Proceed 1995 27:3092 3.
86. Page B, Thervet E, Legendre C et al. Cryptococcosis after renal transplantation. Transplant Proceed 1999 27:1732.
87. Spector SA, Busch DF, Follansbee S et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis 1995 171:1431 7.
88. Wasler A, Iberer F, Auer T et al. Treatment of leukopenia with granulocyte-macrophage colony-stimulating factor after heart transplantation. Transplant Proceed 1995 27:2633 4.
89. Xiwen B, Lixin Y, Junjie M. Treatment of peripheral leukopenia after cadaveric kidney transplantation. Transplant Proceed 1996 28:1631 2.
90. Trindade E, Maton P, Reding R et al. Use of granulocyte macrophage colony stimulating factor in children after orthotopic liver transplantation. J Hepatology 1998 28:1054 7.
91. Trindade E, Maton P, Reding R et al. Use of granulocyte-macrophage colony-stimulating factor in children after orthotopic liver transplantation. J Hepatol 1998 28:1054 7.
92. MacKenzie K, Baumgarten K, Helm B et al. Innovative medical management with resection for successful treatment of pulmonary mucormycosis despite diagnostic delay. J La State Med Soc 2002 154:82 5.
93. Vales-Albertos L, Andrade-Sierra J, Gomez-Navarro B et al. Nonspecific immunoglobulin and granulocyte-macrophage colony-stimulating actor use in complicated varicella zoster: the first case report in a renal transplant recipient. Transplantation 2006 81:809 10.
94. Gallin J, Farber J, Holland S et al. Interferon-y in the management of infectious diseases. Ann Intern Med 1995 123:216 24.
95. Rex J, Bennett J, Gallin J et al. In vivo interferon-gamma augments in the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 1991 163:849 52.
96. Nagai H, Guo J, Choi H et al. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis 1995 172:1554 60.
97. Roilides E, Blake C, Holmes A et al. Granulocyte-macrophage colony-stimulating factor and inteferon-y prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycology 1996 34:63 9.
98. Bernhisel-Broadbent J, Camargo E, Jeffe H et al. Recombinant human interferon-gamma as adjuvant therapy for Aspergillus infection in a patient with chronic granulomatous disease. J Infect Dis 1991 163:908 11.
99. Pasic S, Abinun M, Pistignjat B et al. Aspergillus osteomyelitis in chronic granulomatous disease: treatment with recombinant gamma-interferon and itraconazole. Pedi Infect Dis J 1996 15:833 4.
100. Saulsbury F. Successful treatment of Aspergillus brain abscess with itraconazole and interferon-y in a patient with chronic granulomatous disease. Clin Infect Dis 2001 32:e137 9.
101. Mamishi S, Zomorodian K, Saadat F et al. A case of invasive aspergillosis in CGD patient successfully treated with amphotericin B and IFN-y. Ann Clin Microbiol Antimicrob 2005 4:4 7.
102. Kelleher AD, Sewell WA, Cooper DA. Effect of protease therapy on cytokine secretion by peripheral blood mononucler cells (PBMC) from HIV-1 infected subjects. Clin Exp Immunol 1999 115:147 52.
103. Summers SA, Dorling A, Boyle JJ et al. Cure of disseminated cryptococcal infection in a renal allograft recipient after the addition of g-interferon to antifungal therapy. Am J Transplantation 2005 5:2067 9.
104. Hidalgo L, Halloran P. Role of IFN-gamma in allograft rejection. Crit Rev Immunol 2002 5:2067 9.
105. Mitchell R, Libby P. Vascular modeling in transplant vasculopathy. Circ Res 2007 100:967 78.
106. Aliff TB, Maslak PG, Jurcic JG et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003 97:1025 32.